Erratum: Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy (Oncotarget (2012) 3 (345-356) DOI: 10.18632/oncotarget.457);Drug-targeted inhibition of peroxisome proliferator-activated receptorγ enhances the chemopreventive effect of anti-estrogen

Oncotarget

Volumn 3, Issue 3, 2012, Pages 345-356

  Yuan, Hongyan ^a   Kopelovich, Levy ^b   Yin, Yuzhi ^a,c   Lu, Jin ^a   Glazer, Robert I ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Er ; Fulvestrant; Gw9662; Ppar

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2-CHLORO-5-NITROBENZANILIDE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANILIDE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARCINOGEN; DRUG DERIVATIVE; ESTRADIOL; FULVESTRANT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL; ARTICLE; CARCINOMA; CHEMICALLY INDUCED DISORDER; CHEMOPROPHYLAXIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; EVALUATION; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MORTALITY; MOUSE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOGENS; CARCINOMA; CHEMOPREVENTION; DRUG SYNERGISM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICROARRAY ANALYSIS; MOLECULAR TARGETED THERAPY; PPAR GAMMA;

EID: 84865694110     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.26161     Document Type: Erratum

References (36)

1. Berger JP, Akiyama TE and Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005; 26(5):244-251.
2. Barish GD, Narkar VA and Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. The Journal of clinical investigation. 2006; 116(3):590-597.
3. Evans RM, Barish GD and Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004; 10(4):355-361.
4. Lehrke M and Lazar MA. The many faces of PPARgamma. Cell. 2005; 123(6):993-999.
5. Michalik L, Desvergne B and Wahli W. Peroxisomeproliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004; 4(1):61-70.
6. Glazer RI, Yuan H, Xie Z and Yin Y. PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate. PPAR Res. 2008; 2008:247379.
7. Kopelovich L, Fay JR, Glazer RI and Crowell JA. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther. 2002; 1(5):357-363.
8. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 2003; 9(1):1-9.
9. Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopelovich L and Glazer RI. Peroxisome proliferatoractivated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 2005; 65(9):3950-3957.
10. Yin Y, Yuan H, Zeng X, Kopelovich L and Glazer RI. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res. 2009; 69(2):687-694.
11. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM and Sporn MB. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPARgamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999; 59(22):5671-5673.
12. Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM and Gonzalez FJ. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis. 2004; 25(9):1747-1755.
13. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM and Fletcher JA. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma Science. 2000; 289(5483):1357-1360.
14. Yin Y, Yuan H, Wang C, Pattabiraman N, Rao M, Pestell RG and Glazer RI. 3-Phosphoinositide-Dependent Protein Kinase-1 Activates the Peroxisome Proliferator-Activated Receptor-{gamma} and Promotes Adipocyte Differentiation. Mol Endocrinol. 2006; 20:268-278.
15. Agostini M, Schoenmakers E, Mitchell C, Szatmari I, Savage D, Smith A, Rajanayagam O, Semple R, Luan J, Bath L, Zalin A, Labib M, Kumar S, Simpson H, Blom D, Marais D, et al. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab. 2006; 4(4):303-311.
16. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM and Blanchard SG. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002; 41(21):6640-6650.
17. Gregory Powell J, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK, Eberhardt NL and McIver B. The PAX8/ PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene. 2004; 23(20):3634-3641.
18. Keller H, Givel F, Perroud M and Wahli W. Signaling crosstalk between peroxisome proliferator-activated receptor/ retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol. 1995; 9(7):794-804.
19. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F and Ando S. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin Cancer Res. 2005; 11(17):6139-6147.
20. Lee H, Finck BN, Jones LA, Welch MJ and Mach RH. Synthesis and evaluation of a bromine-76-labeled PPARgamma antagonist 2-bromo-5-nitro-Nphenylbenzamide. Nucl Med Biol. 2006; 33(7):847-854.
21. Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, Nakamura M, Miao S, Cao P, Learned RM, Chen JL and Li Y. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem. 2002; 277(22):19649-19657.
22. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A. 1999; 96(11):6102-6106.
23. Elbrecht A, Chen Y, Adams A, Berger J, Griffin P, Klatt T, Zhang B, Menke J, Zhou G, Smith RG and Moller DE. L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. J Biol Chem. 1999; 274(12):7913-7922.
24. Seargent JM, Yates EA and Gill JH. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol. 2004; 143(8):933-937.
25. Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y and Grillier-Vuissoz I. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. Breast Cancer Res Treat. 2008.
26. Schaefer KL, Takahashi H, Morales VM, Harris G, Barton S, Osawa E, Nakajima A and Saubermann LJ. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. Int J Cancer. 2007; 120(3):702-713.
27. Cavallo F, Astolfi A, Iezzi M, Cordero F, Lollini PL, Forni G and Calogero R. An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics. 2005; 6 Suppl 4:S7.
28. Yin Y, Bai R, Russell RG, Beildeck ME, Xie Z, Kopelovich L and Glazer RI. Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling. Mol Carcinog. 2005; 44(1):42-50.
29. Astolfi A, Landuzzi L, Nicoletti G, De Giovanni C, Croci S, Palladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, Forni G, Nanni P and Lollini PL. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am J Pathol. 2005; 166(4):1205-1216.
30. David CJ and Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010; 24(21):2343-2364.
31. Nakano R, Kurosaki E, Yoshida S, Yokono M, Shimaya A, Maruyama T and Shibasaki M. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol. 2006; 72(1):42-52.
32. Liu D, Zeng BX, Zhang SH, Wang YL, Zeng L, Geng ZL and Zhang SF. Rosiglitazone, a peroxisome proliferatoractivated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats. Crit Care Med. 2005; 33(10):2309-2316.
33. Burton JD, Castillo ME, Goldenberg DM and Blumenthal RD. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines. Anticancer Drugs. 2007; 18(5):525-534.
34. Kim KR, Choi HN, Lee HJ, Baek HA, Park HS, Jang KY, Chung MJ and Moon WS. A peroxisome proliferatoractivated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Oncol Rep. 2007; 18(4):825-832.
35. Pollock C, Yin Y, Yuan H, Zeng X, King S, Li X, Kopelovich L, Albanese C and Glazer RI. PPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis. PLoSONE. 2011; 6(1):e16215.
36. Yuan H, Upadhyay G, Yin Y, Kopelovich L and Glazer RI. Stem Cell Antigen-1 Deficiency Enhances the Chemopreventive Effect of Peroxisome Proliferator-Activated Receptor{gamma} Activation. Cancer Prev Res (Phila). 2011; 4(12):1-10.